Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lonafarnib: First Approval

1 Feb 2021

Abstract excerpt

Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus (HDV) infections, and progeria and progeroid laminopathies. The drug was originally discovered by Merck & Co as an investigational drug in oncology. In progeria, lonafarnib inhibits farnesyltransferase to prevent farnesylation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Nuclear Structure and Function
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33590450
DOI: 10.1007/s40265-020-01464-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lonafarnib: First ApprovalPMID 33590450Read ↗

Small-Molecule Therapeutic Perspectives for the Treatment of Progeria.Semantic proximity Read ↗

FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathiesSemantic proximity Read ↗

Hutchinson-Gilford Progeria paves the way for novel targeted anti-aging therapies.Semantic proximity Read ↗

An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.Semantic proximity Read ↗

Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson–Gilford Progeria SyndromeSemantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach.Semantic proximity Read ↗

Hutchinson-Gilford progeria syndrome: Rejuvenating old drugs to fight accelerated ageingSemantic proximity Read ↗

Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Unraveling the mysteries of Hutchinson-Gilford progeria syndrome: a comprehensive review of LMNA gene mutations.Semantic proximity Read ↗

Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Increased Telomere Mobility in Progeria is Restored by Isoprenylcysteine Carboxyl Methyltransferase InhibitionSemantic proximity Read ↗

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.